Skip to main content

Table 2 Patient characteristics

From: Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting

Age Mean (SD) 61.6 (9.8)  
   N %
Sex Women 47 56.0%
Men 37 44.0%
Previous surgery Yes 23 27.7%
No 60 72.3%
Missing 1  
Previous radiotherapy Yes 8 10.1%
No 71 89.9%
Missing 5  
Regimens (1st line) pemetrexed/cisplatin 34 40.5%
pemetrexed/carboplatin 28 33.3%
pemetrexed/ cisplatin (switch to pemetrexed/carboplatin) 9 10.7%
vinorelbine/carboplatin 7 8.3%
vinorelbine/cisplatin 2 2.4%
pemetrexed/carboplatin, (second vinorelbine/carboplatin) 2 2.4%
pemetrexed/carboplatin (reinduction with pemetrexed/cisplatin) 1 1.2%
pemetrexed/etoposid 1 1.2%
Cycles 1 cycle 3 3.6%
2 cycles 7 8.3%
3 cycles 12 14.3%
4 cycles 57 67.9%
5 cycles 2 2.4%
6 cycles 2 2.4%
8 cycles 1 1.2%